Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Yale New Haven Children's Hospital becomes first in Connecticut to perform pediatric heart transplants

Yale New Haven Children's Hospital (YNHCH) today announced that it has become the first hospital in Connecticut and Rhode Island to receive certification from the United Network of Organ Sharing (UNOS) to perform pediatric heart transplants.

21 Feb 2019

Study sheds new light on left ventricular dysfunction in ischemic heart disease

Ischemic heart disease is a growing cause of heart failure owing to the increasing prevalence of diabetes, hypertension, and obesity.

17 Feb 2019

Study findings hold promise for children with DMD

Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects.

11 Feb 2019

New study compares chemotherapy drugs with development of cardiomyopathy

In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.

1 Feb 2019

SPECT imaging combined with cardiac MRI could help improve ventricular tachycardia ablation

Adding functional imaging to structural imaging of patients with ventricular tachycardia (VT) has the potential to improve current VT ablation strategies, according to new research published in the January issue of The Journal of Nuclear Medicine.

30 Jan 2019

Scientists pinpoint a hidden culprit in heart failure

An international research team led by scientists at the University of Alberta have pinpointed a hidden culprit that leads to dilated cardiomyopathy--a dangerous condition that accounts for 20 per cent of all cases of heart failure--which opens the door to potential new treatments that could help counter the threat.

10 Jan 2019

Study reveals heart cell defect as possible cause of heart failure in pregnancy

Peripartum cardiomyopathy is a rare form of heart failure that affects women in their last month of pregnancy and up to five months after giving birth. PPCM can be difficult to detect because its symptoms -- swelling in the feet and legs and shortness of breath -- mimic many of those of third trimester pregnancy.

2 Jan 2019

The impact of maternal diabetes on fetal heart development

Congenital heart disease is the most common birth defect. And even with remarkable advances in care, it remains the leading cause of non-infectious death in infants.

24 Dec 2018

Revolutionary ‘Heart in a Box’ transplantees hope for a bright future this Christmas

Last year two critically ill heart patients were facing an uncertain future, but this Christmas Scotland’s first revolutionary ‘Heart in a Box’ transplantees are looking forward with hope.

21 Dec 2018

Experimental gene therapy extends lifespan of mice suffering from untreatable mitochondrial disease

Researchers at the University of Helsinki and Folkhälsan Research Center have, together with their collaborators, for the first time demonstrated in a mouse model that partial restoration of respiratory chain function in mitochondria, which serve as cellular power plants, may be sufficient to entirely prevent symptoms of a severe mitochondrial disorder.

20 Dec 2018

FDA takes significant step forward in driving development of novel genetic tests

The U.S. Food and Drug Administration today took a significant step forward in driving the efficient development of novel diagnostic technologies that scan a person's DNA to diagnose genetic diseases and guide medical treatments.

5 Dec 2018

Study elucidates genetic causes of severe cardiomyopathies in children

Cardiac muscle degeneration (cardiomyopathy) is the most common cause of severe cardiac dysfunction and life-threatening cardiac arrhythmias in children. These severe disorders often lead to consideration of heart transplant. However, their actual cause - the genetic basis - has been poorly characterized.

7 Nov 2018

Ultromics expands multiple clinical trials for coronary heart disease to the U.S.

Ultromics is currently supporting multiple ongoing clinical trials including “Rainier”, based in the U.S., and “EVAREST”, in the UK.

19 Oct 2018

Researchers discover why heart contractions are weaker in individuals with HCM

When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy. Itis the most common genetic heart disease in the US and affects an estimated 1 in 500 people around the world.

17 Oct 2018

Study uncovers important role of PRMT1 in dilated cardiomyopathy

In a study published in iScience, Professor Akiyoshi Fukamizu of the Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (University of Tsukuba, JAPAN) and the research group reported a new work on discovery of the important role of PRMT1 in dilated cardiomyopathy.

16 Oct 2018

Micropeptide molecule could be promising gene therapy target to treat heart failure

Researchers have discovered a micropeptide molecule that can restore normal heart function in mice, according to a study in eLife.

10 Oct 2018

Massively parallel single-nucleus RNA sequencing reveals insights into heart disease

Scientists using a powerful new technology that sequences RNA in 20,000 individual cell nuclei have uncovered new insights into biological events in heart disease.

9 Oct 2018

RNA sequencing method uncovers new insights into biological events in heart disease

Scientists using a powerful new technology that sequences RNA in 20,000 individual cell nuclei have uncovered new insights into biological events in heart disease.

5 Oct 2018

Previously unknown genetic causes of mitochondrial diseases identified

An international team of scientists led by researchers from the University of Colorado School of Medicine have identified previously unknown genetic causes of mitochondrial diseases.

3 Oct 2018

Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company's recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation.

24 Sep 2018